Eidos Therapeutics completes $64M Series B financing
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials
SAN FRANCISCO, April 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eidos Thera... Biopharmaceuticals, Venture Capital Eidos Therapeutics, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news
Case: Breast Amyloidosis Detected With 3D Mammography Case: Breast Amyloidosis Detected With 3D Mammography
Review the imaging characteristics of breast amyloidosis in this unusual case. How should definitive diagnosis be made?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news
Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 1, 2018 Category: Drugs & Pharmacology Source Type: news
Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 12, 2017 Category: Drugs & Pharmacology Source Type: news
U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 20, 2017 Category: Drugs & Pharmacology Source Type: news
Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 16, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 16, 2017 Category: Drugs & Pharmacology Source Type: news
Alnylam shares hit all-time high as rare disease drug continues to impress
Alnylam Pharmaceuticals added more than $1.5 billion to its market cap on Thursday after unveiling new data from a closely watched trial of its lead rare disease drug, which appeared to outperform a competitor ’s drug targeting the same disorder.
Alnylam (Nasdaq: ALNY) reported new details from a Phase 3 trial of patisiran, a potential treatment for a disease called amyloidosis that affects around 10,000 people. The company previously said in September that the study had met all of its goals,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Inotersen Shows Efficacy in Hereditary ATTR Inotersen Shows Efficacy in Hereditary ATTR
Improvements in neurologic and quality-of-life endpoints were seen in patients with hereditary transthyretin amyloidosis with polyneuropathy by using the investigational drug inotersen; side effects were called ' monitorable. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
BU researcher receives NIH award to better understand wild-type transthyretin amyloidosis
(Boston University School of Medicine) Lawreen H. Connors, PhD, associate professor of pathology and laboratory medicine and biochemistry at Boston University School of Medicine (BUSM), is the recipient of a National Institutes of Health (NIH) High Priority, Short-Term Project Award, for her research 'molecular mechanism of senile cardiac amyloidosis.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2017 Category: International Medicine & Public Health Source Type: news
Experimental Alnylam drug hits mark in late-stage study, lifting shares
Alnylam Pharmaceuticals said Wednesday that its lead experimental drug for a rare disease had passed a late-stage trial, adding more than $1.5 billion to the Cambridge company ’s market cap in pre-market trading and potentially paving the way for a first-of-its-kind treatment to hit the market.
Alnylam (Nasdaq: ALNY) said that the Phase 3 study of patisiran, which targets a disease called amyloidosis that affects around 10,000 people, had met all of its goals. Import antly, the company and its… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
Distal Bicep Tendon Rip Tied to Transthyretin Amyloidosis
Findings in patients with heart failure with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Orthopedics, Pathology, Pulmonology, Journal, Source Type: news
Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments
(Johns Hopkins Medicine) Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease -- familial transthyretin amyloidosis -- the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news
X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter.
-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 27, 2017 Category: Consumer Health News Source Type: news
X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter.
-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - March 27, 2017 Category: Science Source Type: news
Discovery's Edge: Cell research on amyloidosis
At Mayo Clinic, Marina Ramirez-Alvarado, Ph.D., studies one type of protein abnormality associated with a complex and incurable disease called light chain amyloidosis. This type of amyloidosis is the most common and can affect the heart, kidneys, skin, nerves, and liver.?Dr. Ramirez-Alvarado and her team just published a paper on their most recent findings in [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2017 Category: Databases & Libraries Source Type: news
